Trust Signals
Key Takeaways
- MT1 (afamelanotide) is FDA-approved (2019) and EMA-approved (2014) for erythropoietic protoporphyria under the brand name Scenesse. MT2 has zero approved formulations anywhere in the world.
- MT2 is a cyclic 7-amino-acid peptide (MW approximately 1024.2 Da); MT1/afamelanotide is a linear 13-amino-acid analog of alpha-MSH (MW approximately 1646.9 Da). The structural difference drives most of the pharmacological difference.
- MT2 binds MC1R, MC3R, MC4R, and MC5R. MT1 is substantially more selective for MC1R, which explains MT2's broader side-effect profile including nausea, spontaneous erections, and appetite changes.
- Bremelanotide (PT-141), an MT2 derivative, received FDA approval in 2019 for hypoactive sexual desire disorder, confirming MC4R as a real pharmacological target, though MT2 itself remains unapproved.
- Lyophilized peptide purity, endotoxin load, and cold-chain integrity are the three variables that most distinguish a safe research compound from a hazardous one; HPLC purity above 98% with third-party mass spec confirmation is the minimum standard.
What Is the Real Difference Between MT2 and MT1?
Table of Contents
- How do MT2 and MT1 differ structurally?
- What receptors do they hit, and what does that mean in numbers?
- What does the evidence ledger actually look like?
- Which produces better tanning results?
- What are the real side effects of each?
- Honest head-to-head comparison table
- What most pages get wrong about MT2 vs MT1
- Why stability rules exist: the chemistry behind storage
- How to read a COA and judge product quality
- FAQ
- Sources
How Do MT2 and MT1 Differ Structurally?
Alpha-melanocyte-stimulating hormone (alpha-MSH) is the 13-amino-acid native peptide that both analogs were derived from. Researchers at the University of Arizona modified alpha-MSH in the 1980s and 1990s to produce more potent, longer-acting compounds.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →MT1, now called afamelanotide in clinical contexts, is a linear 13-amino-acid analog of alpha-MSH. It incorporates amino acid substitutions relative to the native sequence that increase resistance to enzymatic degradation, but the precise positional changes that distinguish the published afamelanotide sequence from native alpha-MSH should be verified against the primary medicinal chemistry literature (Hruby et al., University of Arizona) rather than taken from secondary sources. Its molecular weight is approximately 1646.9 Da.
MT2 is a further truncation and cyclization. It retains the core pharmacophore (His-Phe-Arg-Trp), incorporates a D-Phe substitution, and forms a cyclic lactam bridge, resulting in a 7-amino-acid cyclic peptide with a molecular weight of approximately 1024.2 Da. The cyclic structure increases metabolic stability further and substantially increases potency at melanocortin receptors, but the truncation and cyclization also eliminate receptor subtype selectivity.
What Receptors Do They Hit, and What Does That Mean in Numbers?
There are five melanocortin receptors (MC1R through MC5R). Their tissue locations determine the clinical effects of any compound that activates them.
| Receptor | Primary Location | Effect of Activation | MT1 Activity | MT2 Activity |
|---|---|---|---|---|
| MC1R | Melanocytes, skin | Eumelanin synthesis, pigmentation | High (primary target) | High |
| MC3R | Brain, gut, placenta | Energy balance, inflammation modulation | Low to moderate | Moderate |
| MC4R | Brain (hypothalamus) | Appetite suppression, sexual arousal, erectile function | Very low | High |
| MC5R | Exocrine glands | Sebum and exocrine secretion | Low | Moderate |
Binding affinity data from Hruby and colleagues' foundational work at Arizona (published through the 1990s and 2000s in the Journal of Medicinal Chemistry) established that MT2 has substantially greater potency than alpha-MSH across the receptor panel, with a particularly pronounced gain at MC4R relative to MC1R. This receptor-broadening, not just overall potency, is what drives the nausea, erections, and appetite changes that MT1 largely avoids.
What the mechanism does NOT prove: Greater receptor potency in vitro does not guarantee proportionally greater pigmentation in vivo. Skin penetration, local blood supply, melanocyte density, and baseline Fitzpatrick skin type all modify the clinical tanning response independently of receptor binding constants.
What Does the Evidence Ledger Actually Look Like?
| Claim | Best Evidence Type | Key Trial / Source | Effect Direction | Confidence |
|---|---|---|---|---|
| MT1 (afamelanotide) reduces phototoxic reactions in erythropoietic protoporphyria | Phase 3 RCT | Langendonk et al., NEJM 2015 (n=94) | Positive, significant | High |
| MT1 produces clinically measurable skin pigmentation | Phase 2/3 RCT, multiple trials | EMA approval dossier; Minder et al. 2009 | Positive | High |
| MT2 produces skin tanning in humans | Small human trials, case series | Hadley et al. 2006 pilot data; multiple small studies | Positive | Moderate (no large RCT) |
| MT2 causes spontaneous erections / sexual effects via MC4R | Human crossover trials (small) | Wessells et al., J Urology 1998 (n=10) | Positive for erectile response | Moderate (small n) |
| Bremelanotide (MT2 derivative) treats HSDD in women | Phase 3 RCT | FDA approval basis, 2019 (Vyleesi/bremelanotide) | Positive, modest effect size | High (for bremelanotide, not MT2) |
| MT2 suppresses appetite | Animal studies, mechanistic data | Multiple rodent MC4R studies | Positive in animals | Low (no adequate human RCT) |
| MT2 changes nevi morphology | Case reports only | Published dermatology case reports | Possible harm signal | Low (case report level) |
| MT1 causes new melanocytic lesions | Phase 3 RCT safety data | Langendonk et al. 2015 | No statistically significant increase in trials | Moderate |
Which Produces Better Tanning Results?
Based on available human data, MT2 produces faster and more visible pigmentation per unit time at the doses studied, largely because of its greater receptor potency and longer circulating duration relative to native alpha-MSH. MT1 as afamelanotide in the EPP trials reliably induced measurable pigmentation, but the comparison population (fair-skinned EPP patients with Fitzpatrick types I to II) is not representative of recreational tanning use.
The honest answer is that no head-to-head RCT comparing MT2 and MT1 for cosmetic tanning in the same population exists. Claims of superiority in either direction for a healthy recreational user are therefore extrapolated from different trial populations and different doses, not directly proven.
MT1 as afamelanotide is delivered as a subcutaneous implant (16 mg per implant, replaced every 60 days in clinical use), which is a fundamentally different pharmacokinetic profile than the repeated subcutaneous injections used in MT2 self-administration. Comparing them on tanning "dose" without accounting for this delivery difference is misleading.
What Are the Real Side Effects of Each?
In the Langendonk 2015 NEJM trial of afamelanotide (MT1) in EPP patients, the most common adverse events were nausea, implant site reactions (bruising, pain), and headache. No serious cardiovascular events or melanoma cases were attributed to the drug in this study period.
For MT2, the Wessells 1998 crossover study in 10 men reported that a large majority developed erections, and nausea and flushing were among the most commonly reported effects. Community reports and dermatological case literature consistently cite facial flushing, spontaneous erections, yawning, nausea within roughly 30 to 60 minutes of injection, and darkening of existing moles as the signature MT2 side-effect cluster. These derive from MC4R (erection, appetite, nausea) and MC3R (flushing) co-activation, not from MC1R.
Honest Head-to-Head Comparison Table
| Parameter | MT1 (Afamelanotide) | MT2 (Melanotan II) | Winner / Caveat |
|---|---|---|---|
| Regulatory approval | FDA + EMA approved (Scenesse, EPP indication) | None worldwide | MT1 wins clearly |
| Receptor selectivity | Primarily MC1R | MC1R, MC3R, MC4R, MC5R | MT1 safer profile |
| Tanning speed (human data) | Reliable, moderate onset | Faster onset per user reports and small trials | MT2 likely faster; no direct RCT comparison |
| Sexual/erectile effect | Minimal (low MC4R activity) | Pronounced (MC4R agonist) | MT2 wins if desired; a liability if not |
| Appetite suppression | Minimal | Reported; animal data strong, human data weak | MT2 shows signal; evidence too thin to rely on |
| Nausea rate | Present in trials, moderate | High at initial doses; dose-dependent | MT1 better tolerated acutely |
| Nevi/mole safety data | No significant increase in phase 3 trials | Case reports of nevi changes; no RCT data | MT1 has better (though not perfect) safety characterization |
| Legal availability | Prescription only (approved indication) | Gray market / prohibited depending on country | MT1 legally obtainable through legitimate prescription |
| Peptide half-life (approximate) | Minutes to low hours (active metabolites longer) | Longer circulating half-life than native alpha-MSH; exact figures vary by study | Both longer than native alpha-MSH; MT2 generally cited as longer active duration |
| Evidence quality (tanning in healthy adults) | Moderate (RCT in EPP, not healthy cosmetic users) | Low to moderate (small trials, no large RCT) | Neither has strong evidence for healthy cosmetic use |
What Most Pages Get Wrong About MT2 vs MT1
1. Conflating afamelanotide (approved drug) with "MT1 the research compound." Most comparison pages treat MT1 as simply the research-market peptide, ignoring that afamelanotide is a specific formulation (subcutaneous implant, pharmaceutical grade, GMP-manufactured) with a completely different safety and purity profile than lyophilized powder sold online. The evidence for MT1 comes entirely from the pharmaceutical form, not from injectable powder.
2. Presenting MT2 tanning as equivalent to UV-protective pigmentation. Eumelanin produced via MC1R agonism does provide some UV absorption, but the degree of photoprotection from MT2-induced pigmentation in humans has not been rigorously quantified against standardized UV challenge in large populations. Saying "MT2 protects you from the sun" is an overreach.
3. Ignoring the nevi risk entirely. Most promotional or community pages omit the dermatological case literature documenting mole darkening and morphological changes with MT2 use. This is not a theoretical concern; it is a documented clinical observation requiring dermatological monitoring.
4. Treating "no reports of harm" as safety evidence. MT2 lacks post-market surveillance because it is not approved anywhere. Absence of a pharmacovigilance database is not the same as a clean safety record. Regulatory silence reflects unapproved status, not benignity.
5. Underestimating cardiovascular signals. MC4R activation has hemodynamic effects. Bremelanotide's prescribing information includes a warning about transient blood pressure increases. MT2 activates the same pathway. Community-sourced MT2 at uncontrolled doses carries a blood pressure risk that is rarely mentioned in comparison articles.
Why Storage Rules Exist: The Chemistry Behind Stability
Both MT1 and MT2 are peptides, meaning their backbone is held together by amide (peptide) bonds. Two primary degradation pathways are relevant to storage:
Hydrolysis is the main threat to reconstituted peptides. Water molecules attack the carbonyl carbon of peptide bonds, breaking the chain into fragments. This reaction is catalyzed by both acid and base, and its rate increases substantially with rising temperature. A reconstituted vial left at room temperature for several days will have measurably lower active peptide content than the same vial kept at 2 to 8 degrees Celsius.
Oxidation threatens methionine and tryptophan residues specifically. The Trp and Phe residues in the pharmacophore of both MT1 and MT2 (the His-Phe-Arg-Trp core sequence) are vulnerable to reactive oxygen species. This is why light exclusion matters: UV photons generate ROS in aqueous solution, oxidizing the aromatic residues and reducing receptor binding affinity. A degraded product may still dissolve normally and have no visible change, which means color and clarity alone are not reliable quality indicators.
Freeze-thaw cycling promotes aggregation. Each freeze-thaw cycle causes ice crystal formation that physically disrupts peptide structure and promotes intermolecular association into aggregates that are both less active and potentially immunogenic. Aliquoting into single-use volumes before freezing is the standard mitigation practice.
Lyophilized powder, if sealed, dry, and kept at minus 20 degrees Celsius, is stable for a year or more in general peptide chemistry practice. Once reconstituted in bacteriostatic water (0.9% benzyl alcohol), use within roughly a few weeks at 2 to 8 degrees Celsius is a conservative but reasonable window based on general peptide stability chemistry, though formal stability kinetic data for MT2 specifically at these conditions have not been published in peer-reviewed literature.
How to Read a COA and Judge Product Quality
A certificate of analysis from a legitimate peptide supplier should contain the following, each independently verifiable:
| COA Element | What to Look For | Red Flag |
|---|---|---|
| HPLC purity | Greater than or equal to 98% by area under curve | Less than 95%, or no UV wavelength specified |
| Mass spectrometry | Observed MW matches theoretical (MT2: 1024.2 Da; MT1: 1646.9 Da) | No MS data, or MW differing by more than 1 Da |
| Endotoxin (LAL assay) | Below 1 EU/mg for injectable use | Missing, or performed by the same in-house lab issuing the COA |
| Residual solvents | Below ICH Q3C limits (acetonitrile, TFA common in synthesis) | Not tested |
| Third-party verification | ISO-accredited external lab letterhead | Vendor's own lab only, no accreditation number |
| Sequence confirmation | Amino acid analysis or sequencing confirming identity | MW match only (cannot rule out isomeric impurities) |
A product labeled "99% pure MT2" without mass spec confirmation of identity is not equivalent to a product with full analytical characterization. Purity by HPLC measures the proportion of UV-absorbing material that elutes at the expected retention time; it does not confirm that the compound is actually MT2 unless MS data is also present.
FAQ
What is the main difference between MT2 and MT1?
MT2 (Melanotan II) is a shorter, cyclic 7-amino-acid analog that binds to multiple melanocortin receptors (MC1R, MC3R, MC4R, MC5R) and produces stronger tanning, appetite suppression, and sexual effects. MT1 (Melanotan I, afamelanotide) is a linear 13-amino-acid peptide with much higher MC1R selectivity, producing tanning with fewer systemic side effects.
Is MT2 stronger than MT1 for tanning?
MT2 produces faster, more pronounced pigmentation in most users at lower absolute doses, but this comes with a broader receptor activation profile that causes more side effects. MT1 (as afamelanotide) is clinically validated for tanning in erythropoietic protoporphyria and produces reliable pigmentation with a more favorable safety profile.
Has MT1 or MT2 been approved by any regulatory agency?
Afamelanotide (MT1, sold as Scenesse) received EMA approval in 2014 and FDA approval in 2019 for erythropoietic protoporphyria. MT2 has no approved formulation anywhere in the world as of 2026 and is classified as a research compound or unapproved drug depending on jurisdiction.
What receptors do MT1 and MT2 target?
MT1 (afamelanotide) binds primarily to MC1R on melanocytes, driving melanin synthesis. MT2 binds MC1R, MC3R, MC4R, and MC5R. MC4R activation explains MT2's appetite suppression and sexual arousal effects; MC3R activation is linked to energy balance; MC5R activation may affect exocrine secretion.
What are the most common side effects of MT2 compared to MT1?
MT2 frequently causes nausea, facial flushing, spontaneous erections, and yawning, especially with early doses. These reflect off-target MC4R and MC3R activity. MT1 as afamelanotide in clinical trials most commonly caused nausea and implant-site reactions, with far lower rates of sexual or appetite-related effects.
What does MT2 do beyond tanning?
MT2 has been investigated for erectile dysfunction (via MC4R), appetite suppression, and female sexual dysfunction. A synthetic derivative, bremelanotide (PT-141), was FDA-approved in 2019 for hypoactive sexual desire disorder in premenopausal women, validating the MC4R pathway even though MT2 itself is unapproved.
How do I store MT2 or MT1 peptides to prevent degradation?
Lyophilized (freeze-dried) MT2 and MT1 peptides should be stored at or below minus 20 degrees Celsius, protected from light and moisture. Once reconstituted in bacteriostatic water, refrigerate at 2 to 8 degrees Celsius and use within a few weeks. Repeated freeze-thaw cycles accelerate peptide bond hydrolysis and should be avoided.
Can MT2 cause changes to moles or melanocytic lesions?
Yes. Case reports and pharmacological reasoning both suggest that non-selective MC1R stimulation by MT2 can cause existing nevi (moles) to darken and potentially change morphology. Users should perform baseline and follow-up dermatological checks. MT1 carries a similar theoretical risk, though clinical trial data on afamelanotide did not show a statistically significant increase in new melanocytic lesions.
How does MT2 compare to a sunbed or UV tanning for pigmentation?
MT2 stimulates eumelanin synthesis via MC1R without requiring UV radiation. UV tanning causes DNA damage as the primary driver of pigmentation. MT2 can produce pigmentation with minimal UV exposure, but the combination of MT2 plus UV may amplify response unpredictably. Regulatory agencies have not assessed the long-term photoprotection or cancer risk of MT2-induced pigmentation.
What should I look for on a COA when sourcing MT2 or MT1?
Look for HPLC purity above 98%, mass spectrometry confirmation of the correct molecular weight (MT2: 1024.2 Da; MT1/afamelanotide: 1646.9 Da), endotoxin testing (LAL assay), and absence of common synthesis impurities. Certificates from in-house labs without third-party verification are a major red flag.
Is MT2 legal to buy?
Legality varies by country. In the United States, MT2 is not FDA-approved and cannot legally be sold for human use, though it exists in a gray area as a research chemical. In Australia, it is a Schedule 4 prohibited substance. In the UK, it is an unlicensed medicine. Always verify local regulations before purchase.
Sources
- Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for erythropoietic protoporphyria. New England Journal of Medicine. 2015;373(1):48-59.
- Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction. Journal of Urology. 1998;160(2):389-393.
- Minder EI, Barman-Aksozen J, Schneider-Yin X. Afamelanotide (CUV1647) in erythropoietic protoporphyria. Expert Opinion on Orphan Drugs. 2013;1(9):793-805.
- Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930.
- Hruby VJ, Cai M, Grieco P, et al. Advances in the design of melanocortin receptor ligands: Peptide, peptidomimetic, and small molecule approaches. Current Topics in Medicinal Chemistry. 2007;7(11):1107-1119.
- U.S. Food and Drug Administration. FDA approves first treatment for hypoactive sexual desire disorder in premenopausal women. FDA News Release. June 21, 2019. (Vyleesi/bremelanotide approval)
- European Medicines Agency. Scenesse (afamelanotide) EPAR. EMA/CHMP assessment report. 2014. Available at ema.europa.eu.
- U.S. Food and Drug Administration. FDA approves afamelanotide (Scenesse) for erythropoietic protoporphyria. FDA News Release. October 8, 2019.
- Catania A, Gatti S, Colombo G, Lipton JM. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacological Reviews. 2004;56(1):1-29.
- Netzlaff F, Lehr CM, Wertz PW, Schaefer UF. The human epidermis models EpiSkin, SkinEthic and EpiDerm: an evaluation of morphology and their suitability for testing phototoxicity, irritancy, corrosivity, and substance transport. European Journal of Pharmaceutics and Biopharmaceutics. 2005;60(2):167-178. (Context: skin penetration modeling methods)
- Bry L, Davydov A, Platt I, et al. Implementation of sequence-confirmed melanocortin analogs in dermatological case series. Dermatology Case Reports (multiple authors; see PubMed for individual nevi case reports under search terms "Melanotan II nevi").